Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Advancements in biosensor-integrated biomedical devices for early detection of metabolic disorders: a comprehensive review.

Created on 12 Nov 2026

Authors

S Sangeetha, Chellasamy Panneerselvam, Abdulrahman Alasmari, Syed Khasim

Published in

The Analyst. Nov 11, 2026. Epub Nov 11, 2026.

Abstract

Lifestyle, genetic, and environmental influences are implicated in metabolic disorders, an emerging global health concern, including diabetes mellitus, dyslipidaemia, obesity, and hyperuricemia. The success of disease treatment and the prevention of long-term complications depend on the early identification and ongoing monitoring of metabolic markers. Even though these are accurate, traditional approaches for diagnosis are invasive, labor-intensive, and not amenable to real-time monitoring. By enabling the rapid, sensitive, and minimally invasive detection of biomarkers such as glucose, insulin, lipids, and uric acid, recent developments in biosensor-integrated biomedical technology have revolutionized metabolic diagnostics. This review provides a comprehensive overview of the various forms of biosensors, including electrochemical, optical, piezoelectric, and nanobiosensors, and their classification, mechanisms, and detection principles. High-performance materials such as graphene, carbon nanotubes, and metallic nanoparticles have been incorporated to significantly enhance biosensor performance, and microfluidic lab-on-a-chip systems have facilitated the convenience of collecting non-invasive samples of interstitial fluid, perspiration, or saliva. To ensure the analytical precision and clinical reliability of biosensor responses, validation methods based on bioinformatics and High-Performance Liquid Chromatography (HPLC) are highlighted. In addition, continuous monitoring, predictive medicine, and tailored healthcare management have been enabled by the incorporation of artificial intelligence (AI), machine learning (ML), and the Internet of Things (IoT) in wearable and intelligent biomedical devices. Widespread clinical translation is hindered by challenges like sensor drift, biofouling, calibration variability, and regulatory constraints, although tremendous progress has been achieved. Future biosensor technology will be developed towards anticipatory, patient-focused, precision-based management of metabolic disorders by synergistic implementation of nanotechnology, AI-enabled analytics, and telemedicine.

PMID:
43013330
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement